INTRODUCTION
============

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease affecting sacroiliac joints, the axial skeleton, peripheral joints, and entheses. Although conventional treatment including non-steroidal anti-inflammatory drugs (NSAIDs) and physical therapy is the basis of AS therapy, it has limited efficacy \[[@b1-kjim-2018-407]\]. Tumor necrosis factor inhibitor (TNFi), which is used to treat rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), shows efficacy for treating AS with poor response to conventional treatments. However, unlike the options for patients with RA and IBD, the treatment options for AS patients, other than TNFi, are limited.

There are major concerns regarding the adverse effects of TNFi, such as tuberculosis, malignancy, and infection \[[@b2-kjim-2018-407]\]. Hepatotoxicity is also a relatively common adverse effect associated with the use of TNFi \[[@b3-kjim-2018-407]\]. In a United States Food and Drug Administration post-marketing surveillance program, treatment with infliximab or etanercept was associated with more than 130 cases of hepatotoxicity within 5 years \[[@b4-kjim-2018-407]\]. The severity of hepatotoxicity ranges from mild liver enzyme elevation to acute liver failure, though liver failure is very rare \[[@b5-kjim-2018-407],[@b6-kjim-2018-407]\]. The exact mechanism of liver enzyme elevation is unclear, although some reports showed that TNFi was associated with autoimmunity, non-alcoholic fatty liver disease (NAFLD), and reactivation of viral hepatitis \[[@b7-kjim-2018-407]-[@b10-kjim-2018-407]\].

The hepatotoxicity of TNFi in autoimmune diseases including RA, psoriatic arthritis, and IBD has been reported in several studies \[[@b7-kjim-2018-407],[@b11-kjim-2018-407],[@b12-kjim-2018-407]\]. However, there has been little evidence of liver enzyme elevation related to TNFi in AS patients \[[@b8-kjim-2018-407],[@b13-kjim-2018-407]\]. The influence of concomitant hepatotoxic medications such as disease-modifying anti-rheumatic drugs (DMARDs) and immunosuppressants may be less in AS than in other autoimmune diseases. Furthermore, different environmental and genetic factors may influence susceptibility to adverse effects. Therefore, we investigated the incidence and risk factors of liver enzyme elevation related to TNFi in Korean AS patients who previously had normal liver enzymes.

METHODS
=======

Study population
----------------

We retrospectively reviewed the medical records of 363 AS patients receiving TNFi in a tertiary hospital from January 2003 to December 2017. The diagnosis of AS was confirmed according to the modified New York criteria \[[@b14-kjim-2018-407]\]. All patients had normal serum liver enzyme levels at least 6 months before initiation of TNFi treatment. Patients with a history of chronic viral hepatitis, other drug-induced hepatitis, or alcoholic liver disease were excluded. Adalimumab, etanercept, infliximab, or golimumab were used to treat AS patients.

The following demographic and clinical information was collected: demographic data including age, sex, body mass index (BMI, kg/m^2^), and hazardous drinking according to World Health Organization criteria \[[@b15-kjim-2018-407]\]; comorbidities such as diabetes mellitus, hypertension, hyperlipidemia, and NAFLD; concomitant medication including NSAIDs, DMARDs (methotrexate and sulfasalazine), anti-tuberculosis drugs, corticosteroids, and statins; laboratory data including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, bilirubin, antinuclear antibody (ANA), human leukocyte antigen-B27 (HLA-B27) erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).

Liver enzyme elevation was defined as serum AST and/or ALT levels greater than the upper limit of normal (ULN) and consecutively elevated for at least two visits. NAFLD was identified by imaging including ultrasound and computed tomography, which were performed when clinically indicated. The study was approved by the Institutional Review Board (2017-1313) of the Asan Medical Center at Seoul, Korea. Informed consent was waived due to a retrospective design of our study.

Statistical analysis
--------------------

Continuous variables were expressed as mean ± standard deviation or median (interquartile range \[IQR\]). They were compared using the Student's t test or the Mann-Whitney *U* test. Categorized data were expressed as percentiles and compared by chi-square or Fisher's exact test. Cox regression analysis was performed to assess hazard ratio (HR) and 95% confidence interval (CI) for liver enzyme elevation. All data were analyzed using SPSS version 24.0 software (IBM Co., Armonk, NY, USA). A *p* \< 0.05 was considered statistically significant.

RESULTS
=======

Characteristics in TNFi users with or without liver enzyme elevation
--------------------------------------------------------------------

The demographic and clinical characteristics of AS patients are shown in [Table 1](#t1-kjim-2018-407){ref-type="table"}. Among 363 AS patients treated with TNFi, liver enzyme elevation was observed in 86 patients (23.7%). Patients with elevated liver enzyme showed a significantly higher prevalence of male sex, diabetes mellitus, hyperlipidemia, and NAFLD compared to patients with normal liver enzymes. Hyperlipidemia was diagnosed after treatment with TNFi in 32 patients (37.2%) in the elevated liver enzyme group and 52 patients (18.8%) in the normal liver enzyme group. NAFLD was diagnosed after starting TNFi treatment in 16 patients (18.6%) in the elevated liver enzyme group and seven patients (2.5%) in the normal liver enzyme group. There was no significant difference in the proportion of hazardous alcohol use between two groups (10.4% in elevated liver enzyme group vs. 9.1% in normal liver enzyme group). Normal liver enzyme group included patients with inflammatory bowel diseases (four patients), coronary artery diseases (three patients), malignancies (two patients), and polycythemia vera (one patient). Creatinine, ALT, and bilirubin at baseline were relatively increased in the elevated liver enzyme groups; however, the use of other medication, including NSAIDs, statins, and DMARDs, were not different between the two groups. In particular, the use of concomitant DMARDs was observed in 30.0% (methotrexate 60 patients, sulfasalazine 36 patients) of patients in the normal liver enzyme group and 30.2% (methotrexate 19 patients, sulfasalazine 10 patients) of patients in the elevated liver enzyme group. The incidence of liver enzyme elevation in patients who received concomitant DMARDs and TNFi treatment was similar to that in patients who received TNFi alone (23.9% vs. 23.6%, *p* = 0.962).

The most frequently prescribed TNFi was adalimumab, which was used in 42.2% of the normal liver enzyme group and in 50.0% of the elevated liver enzyme group. The proportion of patients receiving infliximab was higher in the normal liver enzyme group than in the elevated liver enzyme group (20.2% vs. 9.3%, *p* = 0.020).

In the elevated liver enzyme group, the median time from TNFi initiation to onset of liver enzyme elevation (latency) was 3.72 months (IQR, 1.77 to 12.51) and the mean peak level of AST/ALT was 60.6/83.9 IU/L. Of the 86 patients in the elevated liver enzyme group, 37.2% (32/86) developed AST and/or ALT elevation greater than two times the ULN. The incidence of AST and/or ALT elevation greater than five times the ULN was 4.6% (4/86) ([Table 2](#t2-kjim-2018-407){ref-type="table"}). The four patients with liver enzyme elevation greater than five times the ULN were all males and had either NAFLD (two patients) or hyperlipidemia (three patients) or both. Furthermore, among the four patients, three underwent ANA testing and the results were all negative. However, the peak total bilirubin level in the elevated AST/ALT group was 1.3 mg/dL (reference range ≤ 1.2 mg/dL).

Clinical factors associated with liver enzyme elevation in patients receiving TNFi
----------------------------------------------------------------------------------

[Table 3](#t3-kjim-2018-407){ref-type="table"} shows the risk factors for liver enzyme elevation in TNFi users. Univariate analysis showed that male sex, diabetes mellitus, hyperlipidemia, NAFLD, and high BMI were associated with liver enzyme elevation. Infliximab was weakly associated with liver enzyme elevation compared to other TNFi (HR, 0.42; 95% CI, 0.20 to 0.88). In multivariate analysis, the independent risk factors of liver enzyme elevation were male sex (HR, 4.62; 95% CI, 1.43 to 15.01), NAFLD (HR, 4.06; 95% CI, 2.11 to 7.84), and hyperlipidemia (HR, 2.53; 95% CI, 1.38 to 4.64). The use of concomitant medications and laboratory findings such as ANA, HLA-B27, baseline ESR, and CRP were not associated with liver enzyme elevation.

Effects of maintaining or discontinuing TNFi treatment in patients with liver enzyme elevation
----------------------------------------------------------------------------------------------

During the follow-up period, most patients (83 out of 86 patients) with elevated liver enzyme were maintained in TNFi treatment, and 81 of those patients showed decreases in liver enzyme within normal range. Among 78 patients who maintained TNFi after liver enzyme normalization, 62 patients experienced re-elevation of liver enzyme. Two patients showed improvements in liver enzyme after discontinuation of TNFi, which was re-elevated after resuming TNFi ([Fig. 1](#f1-kjim-2018-407){ref-type="fig"}).

Among the 86 patients with liver enzyme elevation, 13 patients were switched to another TNFi during the follow-up period. Liver enzyme elevation even after switching to another TNFi was observed in nine of 13 patients; however, four patients developed normal liver enzymes after switching (two patients switched from adalimumab to etanercept and two patients switched from golimumab to adalimumab) ([Table 4](#t4-kjim-2018-407){ref-type="table"}).

DISCUSSION
==========

In this study, we determined that liver enzyme elevation associated with TNFi therapy is relatively common in Korean AS patients. Male sex, NAFLD, and hyperlipidemia were independently associated with liver enzyme elevation. Switching to another TNFi did not always restore normal serum liver enzyme levels.

The incidence of liver enzyme elevation was 23.7% in our AS patients treated with TNFi. Previous studies showed various incidences, perhaps due to different definitions of liver enzyme elevation \[[@b8-kjim-2018-407],[@b16-kjim-2018-407],[@b17-kjim-2018-407]\]. If the definition of liver enzyme elevation is confined to more than two times the ULN, the incidence of elevated AST/ALT is 8.8% (occurring in 32 of 363 TNFi recipients) in our study. This result is comparable to those reported previously \[[@b8-kjim-2018-407],[@b12-kjim-2018-407]\]. Furthermore, the median latency was 3.72 months (almost 15 weeks), which is also similar to the results of previous studies showing 14 to 18 weeks of median latency for TNFi-induced hepatotoxicity \[[@b12-kjim-2018-407],[@b16-kjim-2018-407]\].

There are several hypotheses regarding the mechanism of TNFi-related hepatotoxicity in previous studies ([Table 5](#t5-kjim-2018-407){ref-type="table"}). One hypothesis posits autoimmunity as the cause. It is well known that some individuals receiving TNFi therapy develop autoimmunity with high levels of autoantibodies. In a previous study, positive ANA, a marker of autoimmune hepatitis, was found at the time of diagnosis of drug-induced liver injury in 73% of patients (8/11) receiving TNFi \[[@b16-kjim-2018-407]\]. However, a positive ANA was not found in our AS patients who developed liver enzyme elevation greater than five times the ULN.

On the other hand, liver steatosis has also been considered a cause of liver enzyme elevation. Underlying NAFLD is a known risk factor of drug-induced liver disease \[[@b18-kjim-2018-407]\]. In a previous study of AS patients treated with etanercept, high BMI was associated with liver enzyme elevation, and hepatic steatosis was observed in five of six patients with liver enzyme elevation \[[@b8-kjim-2018-407]\]. These findings suggest that, although the mechanism has not been fully identified \[[@b19-kjim-2018-407],[@b20-kjim-2018-407]\], aggravation of NAFLD might have contributed substantially to the development of liver enzyme elevation in our patients. Recent studies have yielded interesting clues about the association between TNFi and NAFLD in IBD patients \[[@b21-kjim-2018-407]\]. Intrahepatic fat disposition was inhibited by TNFi in individuals with active IBD, while in those with inactive IBD, a metabolic mechanism that induced fatty liver disease was promoted by TNFi, associated with insulin resistance and weight gain \[[@b22-kjim-2018-407]\]. Therefore, liver enzyme elevation in our AS patients after several months of TNFi exposure might have resulted from fatty liver change through a metabolic mechanism followed by inflammation control.

In the present study, male sex was the other risk factor of liver enzyme elevation in patients treated with TNFi. In drug-induced liver injury, women are usually more susceptible \[[@b23-kjim-2018-407]\]. However, some medications, such as azathioprine, are more likely to cause liver enzyme elevation in men than in women \[[@b24-kjim-2018-407]\]. Pharmacokinetics and pharmacodynamics differ in men and women due to such factors as hormonal effects, body weight, body composition, and gender-specific differences in the immune system \[[@b25-kjim-2018-407]\]. AS also shows a male predominance. Specific genetic polymorphism in AS might contribute to the gender difference in liver enzyme elevation.

Infliximab showed a weaker association with liver enzyme elevation than other TNFi in univariate analysis, but the association disappeared in the multivariate analysis. This finding was different from those of previous reports showing that infliximab was the most common TNFi to induce liver injury \[[@b16-kjim-2018-407]\]. The reason for this result is not clear; however, infliximab is known to induce more ANA reactivity than etanercept and to promote liver enzyme elevation with autoimmunity \[[@b16-kjim-2018-407],[@b26-kjim-2018-407]\]. In contrast, in a previous study involving individuals with AS, the mean levels of serum liver enzyme at 12 months after initiation of TNFi were higher with adalimumab than infliximab or etanercept treatment, although they were within the normal range \[[@b13-kjim-2018-407]\]. The dose of infliximab also might be one of the causes of this inconsistency. In previous studies, patients treated with a lower dose of infliximab developed liver enzyme elevation more frequently than patients treated with a standard dose \[[@b12-kjim-2018-407],[@b16-kjim-2018-407]\]. The standard dose of infliximab is generally higher in patients with AS (5 mg/kg) than that in those with RA (3 mg/kg) \[[@b27-kjim-2018-407]\]. Therefore, the results in our AS patients suggest that the use of infliximab is not a risk factor for liver enzyme elevation and that infliximab is comparable to other TNFi regarding hepatotoxicity.

Cross-reactivity when switching to another TNFi occurred uncommonly in previous studies \[[@b28-kjim-2018-407]-[@b30-kjim-2018-407]\]. This finding might be due to the differences of drug chemical structure and polymorphism of the TNF-alpha gene \[[@b31-kjim-2018-407]\]. However, we showed that other TNFi also induced liver enzyme elevation in some patients. This observation may relate to the similar mechanisms of effect among tumor necrosis factor inhibitors, and to the possible function of TNF to promote liver regeneration \[[@b32-kjim-2018-407]\].

This study had several limitations. Many other medical conditions that could affect liver enzyme elevation were not fully identified in this retrospective study. Also, liver biopsies were not examined, so the mechanism of hepatotoxicity was not determined.

In conclusion, we observed liver enzyme elevation after TNFi exposure in 23.7% of AS patients who previously had normal liver enzyme levels. The risk of liver enzyme elevation was increased in male AS patients and in AS patients with NAFLD or hyperlipidemia. Switching to another TNFi appears to have limited utility for restoring normal liver function.

KEY MESSAGE
===========

1\. Liver enzyme elevation was a relatively common adverse effect of tumor necrosis factor (TNF) inhibitor therapy in patients with ankylosing spondylitis.

2\. Male sex, non-alcoholic fatty liver disease, and hyperlipidemia were important factors associated with liver enzyme elevation in patients with ankylosing spondylitis treated with TNF inhibitors.

3\. Liver enzyme elevation was often observed even after switching to another TNF inhibitor.
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###### 

Comparison of demographic, clinical, and laboratory findings in AS patients receiving TNF inhibitors

  Characteristic                      Normal liver enzyme (n = 277)   Elevated liver enzyme (n = 86)   *p* value
  ----------------------------------- ------------------------------- -------------------------------- -----------
  Age at diagnosis, yr                33.9 (14.2)                     33.5 (13.6)                      0.852
  Age at onset of TNF inhibitor, yr   37.9 (13.7)                     37.1 (13.1)                      0.628
  Disease duration, mon               110.19 (78.4)                   121.90 (71.1)                    0.218
  Male sex                            198 (71.5)                      78 (90.7)                        \< 0.001
  Diabetes mellitus                   7 (2.5)                         7 (8.1)                          0.026
  Hypertension                        48 (17.3)                       19 (22.1)                        0.320
  Chronic kidney disease              7 (2.5)                         0                                0.205
  Hyperlipidemia                      72 (26.0)                       48 (55.8)                        \< 0.001
  NAFLD                               12 (4.3)                        19 (22.1)                        \< 0.001
  Smoker                              137/270 (50.7)                  51/85 (60.0)                     0.136
  Hazardous drinking                  16/175 (9.1)                    5/48 (10.4)                      0.783
  BMI, kg/m^2^                        24.08 (6.25)                    25.53 (2.94)                     0.044
  ANA                                 15/123 (12.2)                   3/41 (7.3)                       0.566
  HLA-B27                             228/250 (91.2)                  71/77 (92.2)                     0.782
  History of AST/ALT elevation        53 (19.1)                       22 (25.6)                        0.197
  Concomitant medication                                                                               
   NSAID                              254 (91.7)                      80 (93.0)                        0.692
   Statin                             36 (13.0)                       10 (11.6)                        0.739
   Latent TB prophylaxis              106 (38.3)                      39 (45.3)                        0.241
   Corticosteroid                     72 (26.0)                       16 (18.6)                        0.163
   DMARDs                             83 (30.0)                       26 (30.2)                        0.805
  TNF inhibitor                                                                                        
   Adalimumab                         117 (42.2)                      43 (50.0)                        0.205
   Etanercept                         81 (29.2)                       27 (31.4)                        0.703
   Infliximab                         56 (20.2)                       8 (9.3)                          0.020
   Golimumab                          23 (8.3)                        8 (9.3)                          0.825
  Laboratory findings                                                                                  
   Baseline creatinine, mg/dL         0.78 ± 0.17                     0.82 ± 0.15                      0.025
   Baseline AST, IU/L                 20.33 ± 5.36                    21.60 ± 6.07                     0.083
   Baseline ALT, IU/L                 13.65 ± 6.17                    17.53 ± 6.82                     \< 0.001
   Baseline ALP, IU/L                 82.82 ± 26.32                   86.53 ± 20.64                    0.236
   Baseline bilirubin, mg/dL          0.61 ± 0.23                     0.67 ± 0.22                      0.048
   Baseline albumin, mg/dL            4.18 ± 2.37                     4.15 ± 0.33                      0.908
   Baseline ESR, mm/hr                43.63 ± 28.13                   46.57 ± 25.78                    0.389
   Baseline CRP, mg/dL                1.92 ± 2.25                     2.43 ± 2.38                      0.066

Values are presented as mean ± SD or number (%).

AS, ankylosing spondylitis; TNF, tumor necrosis factor; NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; ANA, antinuclear antibody; HLA-B27, human leukocyte antigen-B27; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NSAID, non-steroidal anti-inflammatory drug; TB, tuberculosis; DMARD, disease-modifying anti-rheumatic drug; ALP, alkaline phosphatase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

###### 

Level of elevated AST/ALT in AS patients receiving TNF inhibitors

  Liver enzyme levels         Elevated liver enzyme (n = 86)
  --------------------------- --------------------------------
  2 ≥ AST or ALT \> 1 × ULN   54 (62.8)
  3 ≥ AST or ALT \> 2 × ULN   19 (22.1)
  5 ≥ AST or ALT \> 3 × ULN   9 (10.5)
  AST or ALT \> 5 × ULN       4 (4.6)

Values are presented as number (%).

AST, aspartate aminotransferase; ALT, alanine aminotransferase; AS, ankylosing spondylitis; TNF, tumor necrosis factor; ULN, upper limit of normal.

###### 

Risk factors of liver enzyme elevation in AS patients receiving TNF inhibitors

  Characteristic           Univariate analysis   *p* value   Multivariate analysis   *p* value
  ------------------------ --------------------- ----------- ----------------------- -----------
  Male sex                 3.23 (1.56--6.70)     0.002       4.62 (1.43--15.01)      0.011
  Diabetes mellitus        2.40 (1.11--5.20)     0.026                               
  Hypertension             1.26 (0.76--2.10)     0.375                               
  Hyperlipidemia           2.82 (1.84--4.32)     \< 0.001    2.53 (1.38--4.64)       0.003
  NAFLD                    3.90 (2.33--6.51)     \< 0.001    4.06 (2.11--7.84)       \< 0.001
  Smoker                   1.34 (0.87--2.08)     0.182                               
  Hazardous drinking       1.23 (0.49--3.12)     0.658                               
  BMI                      1.03 (1.01--1.06)     0.010                               
  Baseline creatinine      3.25 (0.98--10.75)    0.054                               
  Baseline ALT             1.06 (1.04--1.08)     \< 0.001    1.14 (1.09--1.19)       \< 0.001
  Baseline bilirubin       2.10 (0.86--5.15)     0.104                               
  Baseline CRP             1.08 (1.00--1.17)     0.570                               
  ANA                      0.63 (0.20--2.07)     0.453                               
  Concomitant medication                                                             
   NSAID                   0.96 (0.42--2.20)     0.918                               
   Statin                  0.72 (0.37--1.39)     0.322                               
   Latent TB prophylaxis   1.20 (0.78--1.83)     0.401                               
   Corticosteroid          0.66 (0.38--1.13)     0.130                               
   DMARDs                  1.08 (0.71--1.65)     0.732                               
  TNF inhibitor                                                                      
   Adalimumab              1.47 (0.96--2.24)     0.078                               
   Etanercept              1.01 (0.64--1.60)     0.961                               
   Infliximab              0.42 (0.20--0.88)     0.020                               
   Golimumab               1.08 (0.52--2.23)     0.843                               

Values are presented as hazard ratios (95% confidence interval). Variables with *p* \< 0.2 on univariate analysis were included in multivariate analysis and variables with *p* \< 0.05 were presented.

AS, ankylosing spondylitis; TNF, tumor necrosis factor; NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; ALT, alanine aminotransferase; CRP, C-reactive protein; ANA, antinuclear antibody; NSAID, non-steroidal anti-inflammatory drug; TB, tuberculosis; DMARD, disease-modifying anti-rheumatic drug.

###### 

Switching to another TNF inhibitor in AS patients with liver enzyme elevation

  Switching TNF inhibitor   Switching to another TNF inhibitor (n = 13)   Normalization after switching (n = 4)
  ------------------------- --------------------------------------------- ---------------------------------------
  Adalimumab → Etanercept   5                                             2
  Adalimumab → Infliximab   2                                             0
  Etanercept → Adalimumab   2                                             0
  Etanercept → Golimumab    1                                             0
  Infliximab → Golimumab    1                                             0
  Golimumab → Adalimumab    2                                             2

TNF, tumor necrosis factor; AS, ankylosing spondylitis.

###### 

Reports of liver enzyme elevation in patients treated with TNF inhibitor

  Study                                         Case   Female   Age, yr   Disease                                  TNF inhibitor          Autoantibodies   Autoimmune feature in liver biopsy   Treatment with steroid   Improvement of liver enzyme elevation
  --------------------------------------------- ------ -------- --------- ---------------------------------------- ---------------------- ---------------- ------------------------------------ ------------------------ ---------------------------------------
  Ghabril et al. \[[@b7-kjim-2018-407]\]        34     22       41        IBD 12, PsA 6, Ps 7, RA 5, AS 3, JIA 1   IFX 26, ETA 4, ADA 4   22/33            15/17                                12                       33
  Bjornsson et al. \[[@b16-kjim-2018-407]\]     11     8        46        IBD 2, RA 6, SpA 1, psoriasis 1, PsA 1   IFX 9, ETA 1, ADA 1    8/11             NA (severe acute hepatitis 3/5)      5                        8
  van Denderen et al. \[[@b8-kjim-2018-407]\]   15     2        43        AS 15                                    ETA 15                 2/12             NA                                   NA                       NA
  Shelton et al. \[[@b12-kjim-2018-407]\]       48     21       32        IBD 48                                   IFX 45, ADA 3          24/26            6/6                                  4                        41
  Rodrigues et al. \[[@b10-kjim-2018-407]\]     8      5        46        IBD 6, RA 1, AS 1                        IFX 7, ADA 1           8/8              8/8                                  8                        6

Values except age are presented as number of cases.

TNF, tumor necrosis factor; IBD, inflammatory bowel disease; PsA, psoriatic arthritis; Ps, psoriasis; RA, rheumatoid arthritis; AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; IFX, infliximab; ETA, etanercept; ADA, adalimumab; SpA, spondyloarthritis; NA, not available.
